RGT vs. CEL, CHLL, MXC, N4P, HELD, HLN, HIK, HCM, INDV, and AMYT
Should you be buying Argent BioPharma stock or one of its competitors? The main competitors of Argent BioPharma include Celadon Pharmaceuticals (CEL), Chill Brands Group (CHLL), Argent BioPharma (MXC), N4 Pharma (N4P), Hellenic Dynamics (HELD), Haleon (HLN), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), and Amryt Pharma (AMYT). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Argent BioPharma vs.
Celadon Pharmaceuticals (LON:CEL) and Argent BioPharma (LON:RGT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, community ranking, analyst recommendations, profitability and risk.
Celadon Pharmaceuticals has higher revenue and earnings than Argent BioPharma. Celadon Pharmaceuticals is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks.
10.7% of Celadon Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.1% of Argent BioPharma shares are owned by institutional investors. 65.1% of Celadon Pharmaceuticals shares are owned by company insiders. Comparatively, 17.8% of Argent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Argent BioPharma's return on equity of 0.00% beat Celadon Pharmaceuticals' return on equity.
In the previous week, Celadon Pharmaceuticals had 2 more articles in the media than Argent BioPharma. MarketBeat recorded 2 mentions for Celadon Pharmaceuticals and 0 mentions for Argent BioPharma. Celadon Pharmaceuticals' average media sentiment score of 0.02 beat Argent BioPharma's score of 0.00 indicating that Celadon Pharmaceuticals is being referred to more favorably in the media.
Celadon Pharmaceuticals received 4 more outperform votes than Argent BioPharma when rated by MarketBeat users.
Celadon Pharmaceuticals has a beta of -0.26, meaning that its stock price is 126% less volatile than the S&P 500. Comparatively, Argent BioPharma has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
Summary
Celadon Pharmaceuticals beats Argent BioPharma on 9 of the 12 factors compared between the two stocks.
Get Argent BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Argent BioPharma Competitors List
Related Companies and Tools
This page (LON:RGT) was last updated on 1/22/2025 by MarketBeat.com Staff
